Winning Points Advisors LLC Takes Position in ImmunityBio, Inc. $IBRX

Winning Points Advisors LLC acquired a new stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 722,373 shares of the company’s stock, valued at approximately $1,430,000. ImmunityBio comprises approximately 1.3% of Winning Points Advisors LLC’s holdings, making the stock its 14th biggest holding.

A number of other large investors have also recently made changes to their positions in IBRX. AQR Capital Management LLC grew its holdings in shares of ImmunityBio by 193.4% during the first quarter. AQR Capital Management LLC now owns 44,448 shares of the company’s stock valued at $134,000 after buying an additional 29,297 shares during the last quarter. Creative Planning grew its holdings in shares of ImmunityBio by 9.2% during the second quarter. Creative Planning now owns 62,028 shares of the company’s stock valued at $164,000 after buying an additional 5,231 shares during the last quarter. Cetera Investment Advisers grew its holdings in shares of ImmunityBio by 56.9% during the second quarter. Cetera Investment Advisers now owns 18,551 shares of the company’s stock valued at $49,000 after buying an additional 6,731 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in ImmunityBio by 5.2% in the second quarter. JPMorgan Chase & Co. now owns 1,071,736 shares of the company’s stock valued at $2,829,000 after purchasing an additional 52,782 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in ImmunityBio by 11.8% in the second quarter. Legal & General Group Plc now owns 205,478 shares of the company’s stock valued at $542,000 after purchasing an additional 21,715 shares during the last quarter. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Stock Up 3.2%

IBRX stock opened at $7.20 on Friday. The company’s 50-day simple moving average is $7.55 and its 200-day simple moving average is $6.12. ImmunityBio, Inc. has a 52-week low of $1.95 and a 52-week high of $12.43. The firm has a market cap of $7.54 billion, a P/E ratio of -8.47 and a beta of 0.03.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Thursday, May 7th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.54). The firm had revenue of $44.21 million for the quarter, compared to analyst estimates of $43.07 million. On average, analysts anticipate that ImmunityBio, Inc. will post -0.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on IBRX. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a report on Monday, February 23rd. D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 price target on shares of ImmunityBio in a report on Tuesday, May 5th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of ImmunityBio in a report on Tuesday, June 2nd. BTIG Research reaffirmed a “buy” rating and issued a $12.00 price target on shares of ImmunityBio in a report on Thursday, May 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, April 14th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, ImmunityBio has a consensus rating of “Moderate Buy” and a consensus target price of $14.20.

Insider Buying and Selling

In other news, Director Barry J. Simon sold 23,033 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $7.18, for a total transaction of $165,376.94. Following the completion of the sale, the director owned 2,827,788 shares in the company, valued at $20,303,517.84. This trade represents a 0.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 69.48% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.